Known targets — ChEMBL curated mechanism
ACHEBDKRB2CHRM1CHRM2CHRM3CHRNA1CHRNB1CHRNDCHRNECHRNGGUCY1A1GUCY1A2GUCY1B1GUCY1B2NAMPTPTAFRSLC10A2SLC6A2SLC6A3TACR1dacAdacBdacCftsImrcAmrcBmrdA
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDPK1 | O15530 | 1/20 | 0.34 |
| ▸ | GDA | Q9Y2T3 | 1/20 | 0.34 |
| ▸ | MAP3K5 | Q99683 | 1/20 | 0.33 |
| ▸ | CDK2 | P24941 | 3/20 | 0.33 |
| ▸ | DPP4 | P27487 | 1/20 | 0.33 |
| ▸ | CDK1 | P06493 | 2/20 | 0.31 |
| ▸ | CCNB1 | P14635 | 2/20 | 0.31 |
| ▸ | CCNA2 | P20248 | 2/20 | 0.31 |
| ▸ | CCNA1 | P78396 | 2/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | CHUK | O15111 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10579996 | 0.98 | PDPK1 (0.35) | PDPK1GDAMAP3K5CDK2DPP4 | |
| Hydrochloric Acid SCHEMBL6065682 | 0.76 | MEN1 (0.32) | — | |
| SCHEMBL2938699 | 0.76 | PDPK1 (0.37) | PDPK1GDAMAP3K5CDK2DPP4 | |
| SCHEMBL1675432 | 0.75 | NOS1 (0.39) | PDPK1GDAMAP3K5CDK2DPP4 | |
| 2,6-Diaminopurine SCHEMBL29444619 | 0.75 | GDA (0.48) | PDPK1GDAMAP3K5CDK2DPP4 | |
| 2,6-Diaminopurine SCHEMBL24052 | 0.75 | GDA (0.48) | PDPK1GDAMAP3K5CDK2DPP4 | |
| SCHEMBL28384784 | 0.74 | PDPK1 (0.36) | PDPK1GDAMAP3K5CDK2DPP4 | |
| 2,6-Diaminopurine SCHEMBL6423146 | 0.73 | GDA (0.47) | PDPK1GDAMAP3K5CDK2DPP4 | |
| 2,6-Diaminopurine SCHEMBL8757968 | 0.73 | GDA (0.47) | PDPK1GDAMAP3K5CDK2DPP4 | |
| SCHEMBL8083818 | 0.73 | MEN1 (0.33) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-6116266-A | — | — | None | — | — | JP | disclosed |
| US-7560587-B2 | Bis[urea-urethane] compounds | XEROX CORPORATION (US) | 2009-07-14 | — | — | US | disclosed |
| US-7504502-B2 | Guanidinopyrimidinone compounds and phase change inks containing same | XEROX CORPORATION (US) | 2009-03-17 | — | — | US | disclosed |
| US-20080171877-A1 | GUANIDINOPYRIMIDINONE COMPOUNDS AND PHASE CHANGE INKS CONTAINING SAME | XEROX CORPORATION (US) | 2008-07-17 | — | — | US | disclosed |
| US-7371858-B2 | Guanidinopyrimidinone compounds and phase change inks containing same | XEROX CORPORATION (US) | 2008-05-13 | — | — | US | disclosed |
| US-7317122-B2 | Curable trans-1,2-cyclohexane bis(urea-urethane) compounds | XEROX CORPORATION (US) | 2008-01-08 | — | — | US | disclosed |
| US-7314949-B2 | 1,2-bis(6-(ethylhexyloxycarbonylamino)hexylaminocarbonylamino)cyclohexane; gelling agents for hot melt and phase change inks | XEROX CORPORATION (US) | 2008-01-01 | — | — | US | disclosed |
| US-7220300-B2 | Phase change inks containing bis(urea-urethane) compounds | XEROX CORPORATION (US) | 2007-05-22 | — | — | US | disclosed |
| US-7157601-B2 | Alkylated urea and triaminotriazine compounds and phase change inks containing same | XEROX CORPORATION (US) | 2007-01-02 | — | — | US | disclosed |
| US-7153349-B2 | Phase change inks containing curable trans-1,2-cyclohexane bis(urea-urethane) compounds | XEROX CORPORATION (US) | 2006-12-26 | — | — | US | disclosed |
| US-20040060474-A1 | Guanidinopyrimidinone compounds and phase change inks containing same | XEROX CORPORATION | 2004-04-01 | — | — | US | disclosed |
| US-20040050295-A1 | ALKYLATED TETRAKIS(TRIAMINOTRIAZINE) COMPOUNDS AND PHASE CHANGE INKS CONTAINING SAME | XEROX CORPORATION | 2004-03-18 | — | — | US | disclosed |
| US-5854228-A | Antiviral phosphonomethoxyalkylene purine and pyrimidine derivatives | INSTITUTE OF ORGANIC CHEMISTRY AND BIOCHEMISTRY OF THE ACADEMY OF SCIENCES OF THE CZECH REPUBLIC (CZ) | 1998-12-29 | — | — | US | disclosed |
| US-5650510-A | VIRICIDES OR ANTITUMOR AGENTS | INSTITUTE OF ORGANIC CHEMISTRY AND BIOCHEMISTRY OF THE ACADEMY OF SCIENCES OF THE CZECH REPUBLIC (CZ) | 1997-07-22 | — | — | US | disclosed |
| EP-0269947-B2 | Antiviral phosphonomethoxyalkylene purine and pyrimidine derivatives | ACAD OF SCIENCE CZECH REPUBLIC (CS) | 1996-10-16 | — | — | EP | disclosed |
| JP-H06116266-A | PRODUCTION OF 2-AMINO-6-ALKOXYPURINE | NIPPON KAYAKU CO LTD | 1994-04-26 | — | — | JP | disclosed |
| US-4801710-A | Regioselective synthesis of 9-substituted purine acyclonucleoside derivatives | MERCK & CO., INC. (US) | 1989-01-31 | — | — | US | disclosed |
| EP-0270885-A1 | Synthesis of purin-9-ylalkylenoxymethyl phosphonic acids | Bristol-Myers Squibb Company (US) | 1988-06-15 | — | — | EP | disclosed |
| EP-0269947-A1 | Antiviral phosphonomethoxyalkylene purine and pyrimidine derivatives | INSTITUTE OF ORGANIC CHEMISTRY AND BIOCHEMISTRY OF THE ACADEMY OF SCIENCES OF THE CZECH REPUBLIC (CS) | 1988-06-08 | — | — | EP | disclosed |
| EP-0184473-A1 | Regioselective synthesis of 9-substituted purine acyclonucleoside derivatives | MERCK & CO. INC. (US) | 1986-06-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040060474-A1 | Guanidinopyrimidinone compounds and phase change inks containing same | CCNI, INO80, CCNY | PDPK1 3516/4885GDA 2311/4885MAP3K5 3267/4885 |
| US-20040050295-A1 | ALKYLATED TETRAKIS(TRIAMINOTRIAZINE) COMPOUNDS AND PHASE CHANGE INKS CONTAINING SAME | CCNT1, CCNT2, CCNK | PDPK1 1648/4885GDA 3036/4885MAP3K5 1350/4885 |
| US-20080171877-A1 | GUANIDINOPYRIMIDINONE COMPOUNDS AND PHASE CHANGE INKS CONTAINING SAME | INO80, RPP30, RO60 | PDPK1 2869/4885GDA 3080/4885MAP3K5 1337/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.